These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 11451568

  • 1. Intracellular and extracellular control of activin function by novel regulatory molecules.
    Tsuchida K, Matsuzaki T, Yamakawa N, Liu Z, Sugino H.
    Mol Cell Endocrinol; 2001 Jun 30; 180(1-2):25-31. PubMed ID: 11451568
    [Abstract] [Full Text] [Related]

  • 2. Novel factors in regulation of activin signaling.
    Tsuchida K, Nakatani M, Matsuzaki T, Yamakawa N, Liu Z, Bao Y, Arai KY, Murakami T, Takehara Y, Kurisaki A, Sugino H.
    Mol Cell Endocrinol; 2004 Oct 15; 225(1-2):1-8. PubMed ID: 15451561
    [Abstract] [Full Text] [Related]

  • 3. Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family.
    Tsuchida K, Arai KY, Kuramoto Y, Yamakawa N, Hasegawa Y, Sugino H.
    J Biol Chem; 2000 Dec 29; 275(52):40788-96. PubMed ID: 11010968
    [Abstract] [Full Text] [Related]

  • 4. Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function.
    Bartholin L, Maguer-Satta V, Hayette S, Martel S, Gadoux M, Corbo L, Magaud JP, Rimokh R.
    Oncogene; 2002 Mar 28; 21(14):2227-35. PubMed ID: 11948405
    [Abstract] [Full Text] [Related]

  • 5. Identification and characterization of a PDZ protein that interacts with activin type II receptors.
    Shoji H, Tsuchida K, Kishi H, Yamakawa N, Matsuzaki T, Liu Z, Nakamura T, Sugino H.
    J Biol Chem; 2000 Feb 25; 275(8):5485-92. PubMed ID: 10681527
    [Abstract] [Full Text] [Related]

  • 6. Characterization of isoforms of activin receptor-interacting protein 2 that augment activin signaling.
    Liu ZH, Tsuchida K, Matsuzaki T, Bao YL, Kurisaki A, Sugino H.
    J Endocrinol; 2006 May 25; 189(2):409-21. PubMed ID: 16648306
    [Abstract] [Full Text] [Related]

  • 7. Expression of FLRG, a novel activin A ligand, is regulated by TGF-beta and during hematopoiesis [corrected].
    Maguer-Satta V, Bartholin L, Jeanpierre S, Gadoux M, Bertrand S, Martel S, Magaud JP, Rimokh R.
    Exp Hematol; 2001 Mar 25; 29(3):301-8. PubMed ID: 11274757
    [Abstract] [Full Text] [Related]

  • 8. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer.
    Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X.
    Endocr J; 2008 Mar 25; 55(1):11-21. PubMed ID: 17878607
    [Abstract] [Full Text] [Related]

  • 9. FLRG, member of the follistatin family, a new player in hematopoiesis.
    Maguer-Satta V, Rimokh R.
    Mol Cell Endocrinol; 2004 Oct 15; 225(1-2):109-18. PubMed ID: 15451575
    [Abstract] [Full Text] [Related]

  • 10. The activin binding proteins follistatin and follistatin-related protein are differentially regulated in vitro and during cutaneous wound repair.
    Wankell M, Kaesler S, Zhang YQ, Florence C, Werner S, Duan R.
    J Endocrinol; 2001 Dec 15; 171(3):385-95. PubMed ID: 11739004
    [Abstract] [Full Text] [Related]

  • 11. Evidence for an inhibitory role of bone morphogenetic protein(s) in the follicular-luteal transition in cattle.
    Kayani AR, Glister C, Knight PG.
    Reproduction; 2009 Jan 15; 137(1):67-78. PubMed ID: 18936084
    [Abstract] [Full Text] [Related]

  • 12. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin.
    Sidis Y, Tortoriello DV, Holmes WE, Pan Y, Keutmann HT, Schneyer AL.
    Endocrinology; 2002 May 15; 143(5):1613-24. PubMed ID: 11956142
    [Abstract] [Full Text] [Related]

  • 13. Structural basis for the inhibition of activin signalling by follistatin.
    Harrington AE, Morris-Triggs SA, Ruotolo BT, Robinson CV, Ohnuma S, Hyvönen M.
    EMBO J; 2006 Mar 08; 25(5):1035-45. PubMed ID: 16482217
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells.
    Rejon CA, Hancock MA, Li YN, Thompson TB, Hébert TE, Bernard DJ.
    Cell Signal; 2013 Dec 08; 25(12):2717-26. PubMed ID: 24018044
    [Abstract] [Full Text] [Related]

  • 17. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.
    Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, Heldin CH, Miyazono K.
    J Cell Biol; 1995 Jul 08; 130(1):217-26. PubMed ID: 7790373
    [Abstract] [Full Text] [Related]

  • 18. Purification of recombinant activin A using the second follistatin domain of follistatin-related gene (FLRG).
    Arai KY, Tsuchida K, Li C, Watanabe G, Sugino H, Taya K, Nishiyama T.
    Protein Expr Purif; 2006 Sep 08; 49(1):78-82. PubMed ID: 16737827
    [Abstract] [Full Text] [Related]

  • 19. Activin and bone morphogenetic protein (BMP) signalling during tooth development.
    Heikinheimo K, Bègue-Kirn C, Ritvos O, Tuuri T, Ruch JV.
    Eur J Oral Sci; 1998 Jan 08; 106 Suppl 1():167-73. PubMed ID: 9541221
    [Abstract] [Full Text] [Related]

  • 20. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.
    Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A.
    Endocrinology; 2006 Jul 08; 147(7):3586-97. PubMed ID: 16627583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.